Advanced

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kyle, RA; Child, JA; Anderson, K; Barlogie, B; Bataille, R; Bensinger, W; Blade, J; Boccadoro, M; Dalton, W and Dimopoulos, M, et al. (2003) In British Journal of Haematology 121(5). p.749-757
Abstract
The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is < 30 g/l and the bone marrow clonal cells < 10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is... (More)
The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is < 30 g/l and the bone marrow clonal cells < 10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is greater than or equal to 30 g/l and/or bone marrow clonal cells greater than or equal to 10% but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTI. Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (+/- recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
monoclonal, classification, multiple myeloma, gammopathies
in
British Journal of Haematology
volume
121
issue
5
pages
749 - 757
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000183193700008
  • pmid:12780789
  • scopus:0038509089
ISSN
0007-1048
DOI
language
English
LU publication?
yes
id
91fddecb-ea04-438d-8c12-be9c883e8839 (old id 309833)
date added to LUP
2007-09-17 08:59:55
date last changed
2018-06-17 04:01:49
@article{91fddecb-ea04-438d-8c12-be9c883e8839,
  abstract     = {The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is &lt; 30 g/l and the bone marrow clonal cells &lt; 10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is greater than or equal to 30 g/l and/or bone marrow clonal cells greater than or equal to 10% but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTI. Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (+/- recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.},
  author       = {Kyle, RA and Child, JA and Anderson, K and Barlogie, B and Bataille, R and Bensinger, W and Blade, J and Boccadoro, M and Dalton, W and Dimopoulos, M and Djulbegovic, B and Drayson, M and Durie, B and Facon, T and Fonseca, R and Gahrton, G and Greipp, P and Harousseau, JL and Harrington, D and Hussein, M and Joshua, D and Ludwig, H and Morgan, G and Oken, M and Powles, R and Richardson, P and Roodman, D and San Miguel, J and Shimizu, K and Shustik, C and Sirohi, B and Sonneveld, P and Tricot, G and Turesson, Ingemar and Van Ness, B and Vesole, D and Weber, D and Westin, Jan and Wheatley, K},
  issn         = {0007-1048},
  keyword      = {monoclonal,classification,multiple myeloma,gammopathies},
  language     = {eng},
  number       = {5},
  pages        = {749--757},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group},
  url          = {http://dx.doi.org/},
  volume       = {121},
  year         = {2003},
}